KROS (Keros Therapeutics, Inc.) Stock Financials & Earnings | Market Cap Arena

KROS (Keros Therapeutics, Inc.) Stock Financials & Earnings | Market Cap Arena

KROSKeros Therapeutics, Inc.

Mkt Cap$414M

Healthcare·Biotechnology·🇺🇸 United States·NASDAQ

Revenue (TTM)$244M

Net Income (TTM)$87M

EPS (TTM)$2.30

Free Cash Flow (TTM)$106M

Gross Margin99.5%

Op. Margin27.7%

Net Margin35.7%

FCF Margin43.4%

P/S Ratio (TTM)1.7x

P/E Ratio (TTM)4.8x

YoY Rev Growth+6775.0%

Employees—

Earnings Reports

Revenue & Profitability

Quarter	Revenue	Gross Profit	Op. Income
Q1 23	$0	$0	-$39M
Q2 23	$0	$0	-$41M
Q3 23	$8K	-$543K	-$43M
Q4 23	$143K	$143K	-$46M
Q1 24	$83K	$83K	-$48M
Q2 24	$37K	$37K	-$50M
Q3 24	$388K	$74K	-$59M
Q4 24	$3M	$3M	-$53M
Q1 25	$211M	$211M	$152M
Q2 25	$18M	$18M	-$40M
Q3 25	$14M	$14M	-$15M
Q4 25	$385K	$0	-$29M

Valuation

Quarter	P/S	P/E
Q1 23	—	—
Q2 23	—	—
Q3 23	51735.5x	—
Q4 23	2741.0x	—
Q1 24	1768.7x	—
Q2 24	1527.2x	—
Q3 24	635.8x	—
Q4 24	116.6x	—
Q1 25	1.9x	98.3x
Q2 25	1.8x	22.0x
Q3 25	1.7x	6.4x
Q4 25	1.7x	4.8x

Operating Cash Flow

Quarter	Operating CF	Free CF
Q1 23	-$34M	-$35M
Q2 23	-$31M	-$31M
Q3 23	-$34M	-$35M
Q4 23	-$25M	-$26M
Q1 24	-$45M	-$46M
Q2 24	-$40M	-$40M
Q3 24	-$31M	-$31M
Q4 24	-$46M	-$46M
Q1 25	$161M	$161M
Q2 25	-$30M	-$30M
Q3 25	$3M	$3M
Q4 25	-$27M	-$27M

Capital Expenditures

CapEx

Quarter	CapEx
Q1 23	$1M
Q2 23	$311K
Q3 23	$550K
Q4 23	$541K
Q1 24	$946K
Q2 24	$310K
Q3 24	$386K
Q4 24	$289K
Q1 25	$565K
Q2 25	$720K
Q3 25	$132K
Q4 25	$134K

OpEx vs Revenue Growth (YoY)

Quarter	Revenue Growth	OpEx Growth
Q1 23	—	+61.1%
Q2 23	—	+34.5%
Q3 23	—	+54.7%
Q4 23	—	+45.8%
Q1 24	—	+24.9%
Q2 24	—	+22.1%
Q3 24	+4750.0%	+36.4%
Q4 24	+2027.3%	+20.8%
Q1 25	+254413.3%	+21.9%
Q2 25	+49002.7%	+14.9%
Q3 25	+3575.8%	-49.8%
Q4 25	-87.3%	-47.3%

Stock-Based Compensation

Quarter	SBC ($)	% of Revenue
Q1 23	$6M	—
Q2 23	$0	—
Q3 23	$0	0.0%
Q4 23	$7M	5121.7%
Q1 24	$8M	9722.9%
Q2 24	$9M	23743.2%
Q3 24	$9M	2272.4%
Q4 24	$9M	302.4%
Q1 25	$9M	4.2%
Q2 25	$9M	47.0%
Q3 25	$4M	27.9%
Q4 25	$7M	1897.4%

OpEx Breakdown

Quarter	R&D	G&A	SG&A
Q1 23	$31M	$8M	—
Q2 23	$33M	$9M	—
Q3 23	$34M	—	$9M
Q4 23	$37M	$9M	—
Q1 24	$38M	$10M	—
Q2 24	$41M	$10M	—
Q3 24	$49M	$10M	—
Q4 24	$46M	$11M	—
Q1 25	$49M	$10M	—
Q2 25	$44M	$14M	—
Q3 25	$20M	$10M	—
Q4 25	$18M	$12M	—

Revenue Segments

Quarter	License	Service, Other	Service
Q1 23	$144M	—	—
Q2 23	$144M	—	—
Q1 24	—	$83K	—
Q2 24	—	$37K	—
Q3 24	—	—	$400K
Q1 25	$195M	$16M	—
Q2 25	—	$18M	—
Q3 25	$10M	$4M	—
Q4 25	—	$385K	—

War Chest

Quarter	Cash	Short-term Investments	Total
Q1 23	$351M	$0	$351M
Q2 23	$322M	$0	$322M
Q3 23	$288M	$0	$288M
Q4 23	$331M	$0	$331M
Q1 24	$442M	$0	$442M
Q2 24	$406M	$0	$406M
Q3 24	$531M	$0	$531M
Q4 24	$560M	$0	$560M
Q1 25	$721M	$0	$721M
Q2 25	$690M	$0	$690M
Q3 25	$693M	$0	$693M
Q4 25	$287M	$0	$287M

Shares Outstanding

Shares Outstanding

Quarter	Shares (Diluted)	QoQ Change
Q1 23	28M	+3.8%
Q2 23	30M	+4.3%
Q3 23	30M	+0.2%
Q4 23	30M	+1.5%
Q1 24	29M	-2.3%
Q2 24	36M	+22.6%
Q3 24	36M	-0.0%
Q4 24	40M	+11.7%
Q1 25	41M	+1.7%
Q2 25	41M	-1.0%
Q3 25	41M	+0.0%
Q4 25	38M	-6.8%

Revenue Per Employee

Revenue / Employee

Year	Revenue/Employee	Employees
FY 18	—	—
FY 19	—	—
FY 20	$0	35
FY 21	$335K	60
FY 22	$0	105
FY 23	$1K	105
FY 24	$21K	169
FY 25	$7K	33K